Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HRN003
MIFTS: 40

Heroin Dependence

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Heroin Dependence

About this section

MalaCards integrated aliases for Heroin Dependence:

Name: Heroin Dependence 12 44 15 73

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:9976
MeSH 44 D006556
NCIt 50 C34694
UMLS 73 C0019337
Sources

Summaries for Heroin Dependence

About this section
Disease Ontology : 12 An opiate dependence that involves the continued use of heroin despite problems related to use of the substance.

MalaCards based summary : Heroin Dependence is related to antisocial personality disorder and personality disorder. An important gene associated with Heroin Dependence is MEG3 (Maternally Expressed 3
Intriguingly a genome-wide association study has implicated MEG3 in the vulnerability to heroin addiction.
Dysfunction Pattern: Mutation), and among its related pathways/superpathways is Amphetamine addiction. The drugs Dopamine and Buprenorphine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and pituitary, and related phenotypes are behavior/neurological and nervous system

Sources

Related Diseases for Heroin Dependence

About this section

Diseases related to Heroin Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 antisocial personality disorder 30.5 ANKK1 DRD2
2 personality disorder 30.5 BDNF DRD2 DRD4
3 morphine dependence 30.2 OPRD1 OPRM1
4 major depressive disorder 29.6 BDNF DRD2 DRD4
5 autism 28.8 AUTS2 BDNF DRD2 DRD4
6 cocaine dependence 28.7 DRD2 OPRD1 OPRM1 PDYN
7 substance dependence 28.6 BDNF DRD2 DRD4 OPRD1 OPRM1
8 attention deficit-hyperactivity disorder 28.5 ANKK1 BDNF DRD2 DRD4 OPRM1
9 disease of mental health 28.2 BDNF DRD2 DRD4 OPRM1 PDYN
10 schizophrenia 27.8 BDNF DRD2 DRD4 MIAT
11 delusional disorder 10.6 DRD2 DRD4
12 neonatal abstinence syndrome 10.5 OPRD1 OPRM1
13 pathological gambling 10.5 DRD2 DRD4
14 oppositional defiant disorder 10.5 DRD2 DRD4
15 traumatic brain injury 10.5 BDNF DRD2
16 tic disorder 10.5 DRD2 DRD4
17 separation anxiety disorder 10.5 DRD4 OPRM1
18 taqi polymorphism 10.4 ANKK1 DRD2
19 alexithymia 10.4 ANKK1 DRD2
20 migraine without aura 10.3 DRD2 DRD4
21 brain injury 10.3 BDNF DRD2
22 withdrawal disorder 10.2 OPRM1 PDYN
23 opioid addiction 10.2 DRD2 OPRD1 OPRM1
24 paranoid schizophrenia 10.2 BDNF MIAT
25 early-onset schizophrenia 10.2 BDNF DRD2 DRD4
26 gilles de la tourette syndrome 10.2 BDNF DRD2 DRD4
27 mood disorder 10.2 BDNF DRD2 DRD4
28 psychotic disorder 10.2 BDNF DRD2 DRD4
29 generalized anxiety disorder 10.1 BDNF DRD2
30 obsessive-compulsive disorder 10.1 BDNF DRD2 DRD4
31 tobacco addiction 10.1 ANKK1 DRD2 OPRM1
32 pain agnosia 10.1 OPRM1 PDYN
33 depression 10.1
34 impulse control disorder 10.1 ANKK1 DRD2 DRD4
35 agnosia 10.1 OPRM1 PDYN
36 amnestic disorder 10.0 BDNF PDYN
37 conduct disorder 10.0 DRD2 DRD4
38 hepatitis 10.0
39 borderline personality disorder 10.0
40 opioid abuse 9.9 DRD2 OPRM1 PDYN
41 aging 9.9
42 post-traumatic stress disorder 9.9
43 hepatitis c virus 9.8
44 hepatitis c 9.8
45 novelty seeking personality trait 9.7
46 hepatitis b 9.7
47 acquired immunodeficiency syndrome 9.7
48 neuronitis 9.7
49 glucagonoma 9.7
50 chronic pain 9.7

Graphical network of the top 20 diseases related to Heroin Dependence:



Diseases related to Heroin Dependence
Sources

Symptoms & Phenotypes for Heroin Dependence

About this section

MGI Mouse Phenotypes related to Heroin Dependence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 OPRM1 PDYN AUTS2 BDNF DRD2 DRD4
2 nervous system MP:0003631 9.5 OPRM1 PDYN AUTS2 BDNF DRD2 DRD4
3 no phenotypic analysis MP:0003012 9.1 PDYN AUTS2 BDNF DRD2 OPRD1 OPRM1
Sources

Drugs & Therapeutics for Heroin Dependence

About this section

Drugs for Heroin Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
2
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 40400 644073
3
Heroin Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 561-27-3 5462328
4
Methadone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 76-99-3 4095
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 93-14-1 3516
6
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
7
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
8
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 16590-41-3 5360515
9 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Serotonin Agents Phase 4,Phase 3
14 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Narcotics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Tranquilizing Agents Phase 4,Phase 3,Phase 1
19 Opiate Alkaloids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
20 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Psychotropic Drugs Phase 4,Phase 3,Phase 1
23 Antitussive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Anti-Anxiety Agents Phase 4
25 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26
Serotonin Investigational, Nutraceutical Phase 4,Phase 3 50-67-9 5202
27
Mirtazapine Approved Phase 3 85650-52-8, 61337-67-5 4205
28
Mianserin Approved, Investigational Phase 3 24219-97-4 4184
29
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
30
Morphine Approved, Investigational Phase 3,Phase 2,Phase 1 57-27-2 5288826
31
Amphetamine Approved, Illicit, Investigational Phase 3 300-62-9 5826 3007
32
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
33
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
34
Clonidine Approved Phase 3,Phase 1 4205-90-7 2803
35
Hydromorphone Approved, Illicit Phase 3 466-99-9 5284570
36
Imidacloprid Vet_approved Phase 2, Phase 3 105827-78-9 86418
37
Histamine Phosphate Phase 3 51-74-1 65513
38 Adrenergic Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Central Nervous System Stimulants Phase 3,Phase 1,Phase 2
40 Adrenergic alpha-Antagonists Phase 3,Phase 1
41 Adrenergic Antagonists Phase 3,Phase 1,Not Applicable
42 Serotonin 5-HT2 Receptor Antagonists Phase 3
43 Serotonin Antagonists Phase 3
44 Histamine Antagonists Phase 3
45 Histamine H1 Antagonists Phase 3
46 Neurotransmitter Uptake Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
47 Paliperidone Palmitate Phase 3
48 Dopamine Antagonists Phase 3
49 Dopamine D2 Receptor Antagonists Phase 3
50 Dopamine Uptake Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
2 A Stepwise Strategy Utilizing Buprenorphine and Methadone Completed NCT00310934 Phase 4 methadone;buprenorphine / methadone sequence
3 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
4 Effects of Buspirone in Opiate Withdrawal Completed NCT00326235 Phase 4 Buspirone
5 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4 Naltrexone
6 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
7 Biomarkers of Injectable Extended Release Naltrexone Treatment Active, not recruiting NCT02324725 Phase 4 Naltrexone
8 Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia Unknown status NCT02541526 Phase 3 Mirtazapine;Placebo
9 An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Unknown status NCT02541513 Phase 3 paliparidone
10 An Open Label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Unknown status NCT02541500 Phase 3 Minocycline
11 Memantine as a Supplement to Naltrexone in Treating Heroin Dependence Completed NCT00476242 Phase 2, Phase 3 Vivitrol;memantine
12 Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone Completed NCT01760473 Phase 3 Intranasal challenge drug
13 Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Completed NCT00577408 Phase 3 depot naltrexone;Oral Naltrexone
14 Study Comparing Liquid and Tablet Buprenorphine Formulations - 5 Completed NCT00000302 Phase 3 Buprenorphine
15 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial Completed NCT00684554 Phase 2, Phase 3 Buprenorphine
16 Directly Administered HIV Therapy in Methadone Clinics Completed NCT00279110 Phase 2, Phase 3
17 Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) Completed NCT01447212 Phase 3 Hydromorphone, Injectable;Diacetylmorphine, injectable;Hydromorphone, liquid oral;Diacetylmorphine, liquid oral
18 Buprenorphine for Prisoners Completed NCT00574067 Phase 3 Buprenorphine +OTP;Buprenorphine +CHC;Counseling +OTP;Counseling +CHC
19 Methadone Maintenance for Prisoners Completed NCT00378079 Phase 3 Counseling + Transfer;Counseling + Methadone
20 Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1 Completed NCT00015171 Phase 3 Buprenorphine/naloxone
21 Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Completed NCT00032968 Phase 3 Buprenorphine/naloxone
22 Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1 Completed NCT00032955 Phase 3 Buprenorphine/naloxone
23 Behavioral Drug and HIV Risk Reduction Counseling With MMT in China Completed NCT01389180 Phase 3
24 ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence Completed NCT00678418 Phase 3 VIVITROL® 380 mg;Placebo
25 The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention Recruiting NCT02440152 Phase 2, Phase 3
26 Addiction Treatment in Russia: Oral vs. Naltrexone Implant Active, not recruiting NCT00218426 Phase 2, Phase 3 naltrexone implant;Oral naltrexone;placebo oral and placebo implant
27 Change the Cycle: An RCT to Prevent Injection Initiation Active, not recruiting NCT02774954 Phase 3
28 Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India Withdrawn NCT00709007 Phase 2, Phase 3
29 Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Unknown status NCT00609089 Phase 1, Phase 2
30 Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1 Unknown status NCT00023283 Phase 2 Buprenorphine
31 Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens Completed NCT00218127 Phase 2 Levoacetyl Methadol;Levoacetyl Methadol;Levoacetyl Methadol
32 Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence Completed NCT00332228 Phase 2 depot naltrexone;BNT
33 Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts Completed NCT00142948 Phase 2 Naltrexone;Placebo
34 A Laboratory Model for Heroin Abuse Medications - 8 Completed NCT00000273 Phase 2 opiates
35 Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1 Completed NCT00238914 Phase 2 Naltrexone
36 Effects of Dynorphin 1-13 on Heroin Addiction - 1 Completed NCT00000244 Phase 2 Dynorphin 1 - 13
37 Study of Computer-Based Treatment for Drug Dependence Completed NCT01315184 Phase 2
38 Treatment Efficacy for Drug Abuse and AIDS Prevention - 2 Completed NCT00000211 Phase 2 Buprenorphine
39 Treatment Efficacy for Drug Abuse and AIDS Prevention - 1 Completed NCT00000210 Phase 2 Buprenorphine
40 Addition of Naltrexone to Methadone Taper Completed NCT00135759 Phase 2 Naltrexone;Placebo comparator;naltrexone;naltrexone
41 Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia Completed NCT01863251 Phase 2 Atomoxetine
42 Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone Completed NCT02046252 Phase 2 Oral naltrexone;Naltrexone implant
43 The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1 Completed NCT00158288 Phase 2
44 Pioglitazone for Heroin and for Nicotine Dependence Terminated NCT01395797 Phase 1, Phase 2 PIO;Placebo
45 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1 Withdrawn NCT00000326 Phase 2 Heroin Dependence
46 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2 Withdrawn NCT00000327 Phase 2 Heroin Dependence
47 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6 Withdrawn NCT00000331 Phase 2 Test Drug;Placebo Drug
48 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5 Withdrawn NCT00000330 Phase 2 Opioid-Related Disorders
49 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4 Withdrawn NCT00000329 Phase 2 Opioid-Related Disorders
50 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3 Withdrawn NCT00000328 Phase 2 Opioid-Related Disorders

Search NIH Clinical Center for Heroin Dependence

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: heroin dependence

Sources

Genetic Tests for Heroin Dependence

About this section
Sources

Anatomical Context for Heroin Dependence

About this section

MalaCards organs/tissues related to Heroin Dependence:

41
Brain, Testes, Pituitary, Prefrontal Cortex, Cortex
Sources

Publications for Heroin Dependence

About this section

Articles related to Heroin Dependence:

(show top 50) (show all 241)
# Title Authors Year
1
The long-term impact of post traumatic stress disorder on recovery from heroin dependence. ( 29706174 )
2018
2
Association between stress pathway gene (CRHR1as^CRHBP) polymorphisms and heroin dependence. ( 29853227 )
2018
3
Association of the SOD2 (rs2758339 and rs5746136) polymorphisms with the risk of heroin dependency and the SOD2 expression levels. ( 29459008 )
2018
4
Opioid Receptors Gene Polymorphism and Heroin Dependence in Iran. ( 29967669 )
2018
5
A 35.8 kilobases haplotype spanning ANKK1 and DRD2 is associated with heroin dependence in Han Chinese males. ( 29550268 )
2018
6
Altered gray matter volume and disrupted functional connectivity of dorsolateral prefrontal cortex in men with heroin dependence. ( 29582514 )
2018
7
Risk of Heroin Dependence in Newly Incident Heroin Users. ( 29847618 )
2018
8
Contribution of Genetic Polymorphisms and Haplotypes in DRD2, BDNF, and Opioid Receptors to Heroin Dependence and Endophenotypes Among the Han Chinese. ( 28692418 )
2017
9
Depression and severity of substance dependence among heroin dependent patients with ADHD symptoms. ( 27997065 )
2017
10
Neural Correlates of Drug-Related Attentional Bias in Heroin Dependence. ( 29410620 )
2017
11
Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs. ( 28473157 )
2017
12
DRD2 and ANKK1 genes associate with late-onset heroin dependence in men. ( 28854834 )
2017
13
A novel inhibitor of endocannabinoid catabolic enzymes sheds light on behind the scene interplay between chronic pain, analgesic tolerance, and heroin dependence. ( 27890603 )
2017
14
Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial. ( 28371689 )
2017
15
Influence of Duration of Heroin Dependence on Humoral Immunologic Indicators. ( 27610581 )
2016
16
Association between dopamine D2 receptor gene polymorphisms and the risk of heroin dependence. ( 27819741 )
2016
17
Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients. ( 27010727 )
2016
18
Brain-derived neurotrophic factor serum levels in heroin-dependent patients after 26weeks of withdrawal. ( 26774004 )
2016
19
Genome-Wide Association of Heroin Dependence in Han Chinese. ( 27936112 )
2016
20
Polymorphisms in the 5-hydroxytryptamine receptor 3B gene are associated with heroin dependence in the Chinese Han population. ( 27773795 )
2016
21
Heroin craving and its correlations with clinical outcome indicators in people with heroin dependence receiving methadone maintenance treatment. ( 26773990 )
2016
22
Association between serotonin transporter gene polymorphisms and heroin dependence: a meta-analytic study. ( 27942217 )
2016
23
Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. ( 27664554 )
2016
24
Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence. ( 25781230 )
2015
25
Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome Study. ( 25619110 )
2015
26
The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese heroin-dependent patients. ( 25640280 )
2015
27
QTc Prolongation in Veterans With Heroin Dependence on Methadone Maintenance Treatment. ( 26097838 )
2015
28
Serum brain-derived neurotrophic factor levels and psychotic symptoms in heroin dependence. ( 26343470 )
2015
29
Changes in neurocognition and adherence over six months in HIV-infected individuals with cocaine or heroin dependence. ( 25484035 )
2015
30
Single-nucleotide polymorphisms in dopamine receptor D1 are associated with heroin dependence but not impulsive behavior. ( 25966176 )
2015
31
Acknowledging Heroin Dependence as a Preventable Pediatric Chronic Medical Condition. ( 26163081 )
2015
32
Association between variable number of tandem repeats (VNTR) polymorphism in the promoter region of monoamine oxidase A (MAOA) gene and susceptibility to heroin dependence. ( 26298506 )
2015
33
MalmAP Treatment Referral and Intervention Study (MATRIS)-effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial. ( 26613636 )
2015
34
Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence. ( 25452049 )
2015
35
Evidence for the contribution of genetic variations in regulator of G protein signaling 9 to the genetic susceptibility of heroin dependence. ( 25591550 )
2015
36
GABRB2 Haplotype Association with Heroin Dependence in Chinese Population. ( 26561861 )
2015
37
Comparative gene expression profiling analysis of lymphoblastoid cells reveals neuron-specific enolase gene (ENO2) as a susceptibility gene of heroin dependence. ( 21995595 )
2014
38
Gender differences in prevalence and correlates of antisocial personality disorder among heroin dependent users in compulsory isolation treatment in China. ( 24342175 )
2014
39
Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. ( 24725468 )
2014
40
Association analysis of GABRB3 promoter variants with heroin dependence. ( 25025424 )
2014
41
Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and heroin dependence. ( 25048760 )
2014
42
PTSD risk associated with a functional DRD2 polymorphism in heroin-dependent cases and controls is limited to amphetamine-dependent individuals. ( 23647975 )
2014
43
Factors associated with one year retention to methadone maintenance treatment program among patients with heroin dependence in China. ( 24565169 )
2014
44
[Association study of CNR1, GAD1 and BDNF polymorphisms with male heroin dependence in the Dai population in Yunnan]. ( 25252306 )
2014
45
Excessive suicide mortality and risk factors for suicide among patients with heroin dependence. ( 25456334 )
2014
46
Chronic heroin dependence leading to adrenal insufficiency. ( 25221675 )
2014
47
Comparative study of the perceived quality of life of patients in treatment for cocaine and heroin dependence in Spain: differences by gender and time in treatment. ( 24712297 )
2014
48
Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese population. ( 24498053 )
2014
49
The effect of heroin dependence on resumption of heroin self-administration in rats. ( 24613630 )
2014
50
Gender sameness and difference in recovery from heroin dependence: A qualitative exploration. ( 24041800 )
2014
Sources

Variations for Heroin Dependence

About this section
Sources

Expression for Heroin Dependence

About this section
Search GEO for disease gene expression data for Heroin Dependence.
Sources

Pathways for Heroin Dependence

About this section

Pathways related to Heroin Dependence according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Amphetamine addiction 37
Show member pathways
 10.87 BDNF DRD2 PDYN
Sources

GO Terms for Heroin Dependence

About this section

Cellular components related to Heroin Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynapse GO:0098794 9.26 DRD4 OPRM1
2 dendrite GO:0030425 9.26 BDNF DRD2 OPRM1 PDYN
3 dendrite membrane GO:0032590 9.16 OPRD1 OPRM1
4 axon terminus GO:0043679 8.8 DRD2 OPRD1 PDYN

Biological processes related to Heroin Dependence according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.95 DRD2 DRD4 OPRD1 OPRM1 PDYN
2 chemical synaptic transmission GO:0007268 9.78 OPRD1 OPRM1 PDYN
3 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.62 OPRD1 OPRM1
4 sensory perception of pain GO:0019233 9.62 OPRD1 OPRM1
5 adult locomotory behavior GO:0008344 9.61 DRD4 OPRD1
6 modulation of chemical synaptic transmission GO:0050804 9.6 BDNF DRD2
7 response to cocaine GO:0042220 9.59 DRD2 OPRM1
8 response to morphine GO:0043278 9.58 DRD2 OPRM1
9 regulation of sensory perception of pain GO:0051930 9.58 OPRD1 OPRM1
10 negative regulation of adenylate cyclase activity GO:0007194 9.57 DRD2 OPRM1
11 eating behavior GO:0042755 9.56 OPRD1 OPRM1
12 response to amphetamine GO:0001975 9.54 DRD2 DRD4
13 arachidonic acid secretion GO:0050482 9.52 DRD2 DRD4
14 behavioral response to cocaine GO:0048148 9.51 DRD2 DRD4
15 neuropeptide signaling pathway GO:0007218 9.5 OPRD1 OPRM1 PDYN
16 dopamine receptor signaling pathway GO:0007212 9.49 DRD2 DRD4
17 negative regulation of protein secretion GO:0050709 9.48 DRD2 DRD4
18 dopamine metabolic process GO:0042417 9.46 DRD2 DRD4
19 negative regulation of voltage-gated calcium channel activity GO:1901386 9.43 DRD2 DRD4
20 sensory perception GO:0007600 9.4 OPRM1 PDYN
21 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.37 DRD2 DRD4
22 opioid receptor signaling pathway GO:0038003 9.26 OPRD1 OPRM1
23 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.16 DRD2 DRD4
24 response to histamine GO:0034776 8.96 DRD2 DRD4
25 behavioral response to ethanol GO:0048149 8.8 DRD2 DRD4 OPRM1

Molecular functions related to Heroin Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.71 DRD2 DRD4 OPRD1 OPRM1
2 obsolete signal transducer activity GO:0004871 9.56 DRD2 DRD4 OPRD1 OPRM1
3 neuropeptide binding GO:0042923 9.37 OPRD1 OPRM1
4 dopamine binding GO:0035240 9.32 DRD2 DRD4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.16 DRD2 DRD4
6 opioid receptor activity GO:0004985 8.96 OPRD1 OPRM1
7 dopamine neurotransmitter receptor activity GO:0004952 8.62 DRD2 DRD4
Sources

Sources for Heroin Dependence

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....